Briacell Therapeutics
BCTX
18 hedge funds and large institutions have $14.3M invested in Briacell Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 6 closing their positions.
2,745% more call options, than puts
Call options by funds: $5.66M | Put options by funds: $199K
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
2.8% less ownership
Funds ownership: 19.12% → 16.33% (-2.8%)
10% less funds holding
Funds holding: 20 → 18 (-2)
16% less capital invested
Capital invested by funds: $17M → $14.3M (-$2.75M)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$3.9M |
| 2 |
Jane Street
New York
|
+$313K |
| 3 |
VF
Virtu Financial
New York
|
+$253K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$244K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$115K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
-$7.54M |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$103K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$82K |
| 4 |
BCM
Bluefin Capital Management
New York
|
-$21.1K |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$19.1K |
BCTX Hedge Fund Activity: Q3 2022 in Review
18 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q3 2022, worth a combined $14.3M — down 16% from $17M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BCTX and 4 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 7 added.
The largest buyer was Lynwood Capital Management, adding an estimated $3.9M. The largest seller was K.J. Harrison & Partners, cutting an estimated $7.54M.
- 18 institutional investors held Briacell Therapeutics (BCTX) as of Q3 2022, down from 20 in Q2 2022.
- Funds reported $14.3M of Briacell Therapeutics stock for Q3 2022, down 16% quarter-over-quarter.
- 4 funds opened new Briacell Therapeutics positions in Q3 2022 and 6 closed out, a net change of -2 holders.
- The largest Briacell Therapeutics buyer in Q3 2022 was Lynwood Capital Management, an estimated $3.9M added.
- The largest Briacell Therapeutics seller in Q3 2022 was K.J. Harrison & Partners, an estimated $7.54M sold.
Based on aggregated 13F filings for Q3 2022.